Review Article | Open Access
Asha Jacob, Rongqian Wu, Mian Zhou, Ping Wang, "Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR- Activation", PPAR Research, vol. 2007, Article ID 089369, 5 pages, 2007. https://doi.org/10.1155/2007/89369
Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR- Activation
Curcumin, the phytochemical component in turmeric, is used as a dietary spice and a topical ointment for the treatment of inflammation in India for centuries. Curcumin (diferuloylmethane) is relatively insoluble in water, but dissolves in acetone, dimethylsulphoxide, and ethanol. Commercial grade curcumin contains 10–20% curcuminoids, desmethoxycurcumin, and bisdesmethoxycurcumin and they are as effective as pure curcumin. Based on a number of clinical studies in carcinogenesis, a daily oral dose of 3.6 g curcumin has been efficacious for colorectal cancer and advocates its advancement into Phase II clinical studies. In addition to the anticancer effects, curcumin has been effective against a variety of disease conditions in both in vitro and in vivo preclinical studies. The present review highlights the importance of curcumin as an anti-inflammatory agent and suggests that the beneficial effect of curcumin is mediated by the upregulation of peroxisome proliferator-activated receptor- (PPAR-) activation.
- H. P. T. Ammon and M. A. Wahl, “Pharmacology of Curcuma longa,” Planta Medica, vol. 57, no. 1, pp. 1–7, 1991.
- B. B. Aggarwal, A. Kumar, and A. C. Bharti, “Anticancer potential of curcumin: preclinical and clinical studies,” Anticancer Research, vol. 23, no. 1 A, pp. 363–398, 2003.
- R. A. Sharma, A. J. Gescher, and W. P. Steward, “Curcumin: the story so far,” European Journal of Cancer, vol. 41, no. 13, pp. 1955–1968, 2005.
- S. V. Jovanovic, C. W. Boone, S. Steenken, M. Trinoga, and R. B. Kaskey, “How curcumin works preferentially with water soluble antioxidants,” Journal of the American Chemical Society, vol. 123, no. 13, pp. 3064–3068, 2001.
- Y.-J. Wang, M.-H. Pan, A.-L. Cheng et al., “Stability of curcumin in buffer solutions and characterization of its degradation products,” Journal of Pharmaceutical and Biomedical Analysis, vol. 15, no. 12, pp. 1867–1876, 1997.
- M.-T. Huang, N. Ma, Y.-P. Lu et al., “Effects of curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin on 12--tetradecanoylphorbol-13-acetate-induced tumor promotion,” Carcinogenesis, vol. 16, no. 10, pp. 2493–2497, 1995.
- B. Wahlstrom and G. Blennow, “A study on the fate of curcumin in the rat,” Acta Pharmacologica et Toxicologica, vol. 43, no. 2, pp. 86–92, 1978.
- V. Ravindranath and N. Chandrasekhara, “Absorption and tissue distribution of curcumin in rats,” Toxicology, vol. 16, no. 3, pp. 259–265, 1980.
- V. Ravindranath and N. Chandrasekhara, “In vitro studies on the intestinal absorption of curcumin in rats,” Toxicology, vol. 20, no. 2-3, pp. 251–257, 1981.
- G. M. Holder, J. L. Plummer, and A. J. Ryan, “The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat,” Xenobiotica, vol. 8, no. 12, pp. 761–768, 1978.
- G. Shoba, D. Joy, T. Joseph, M. Majeed, R. Rajendran, and P. S. S. R. Srinivas, “Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers,” Planta Medica, vol. 64, no. 4, pp. 353–356, 1998.
- A.-L. Chen, C.-H. Hsu, J.-K. Lin et al., “Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions,” Anticancer Research, vol. 21, no. 4 B, pp. 2895–2900, 2001.
- R. A. Sharma, H. R. McLelland, K. A. Hill et al., “Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer,” Clinical Cancer Research, vol. 7, no. 7, pp. 1894–1900, 2001.
- R. A. Sharma, S. A. Euden, S. L. Platton et al., “Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance,” Clinical Cancer Research, vol. 10, no. 20, pp. 6847–6854, 2004.
- S. Shishodia, G. Sethi, and B. B. Aggarwal, “Curcumin: getting back to the roots,” Annals of the New York Academy of Sciences, vol. 1056, pp. 206–217, 2005.
- M.-T. Huang, Y.-R. Lou, W. Ma, H. L. Newmark, K. R. Reuhl, and A. H. Conney, “Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice,” Cancer Research, vol. 54, no. 22, pp. 5841–5847, 1994.
- K. M. Mohandas and D. C. Desai, “Epidemiology of digestive tract cancers in India. V. Large and small bowel,” Indian Journal of Gastroenterology, vol. 18, no. 3, pp. 118–121, 1999.
- G. S. Sidhu, A. K. Singh, D. Thaloor et al., “Enhancement of wound healing by curcumin in animals,” Wound Repair and Regeneration, vol. 6, no. 2, pp. 167–177, 1998.
- J. Folkman and Y. Shing, “Angiogenesis,” The Journal of Biological Chemistry, vol. 267, no. 16, pp. 10931–10934, 1992.
- J. Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,” Nature Medicine, vol. 1, no. 1, pp. 27–31, 1995.
- D. Thaloor, A. K. Singh, G. S. Sidhu, P. V. Prasad, H. K. Kleinman, and R. K. Maheshwari, “Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin,” Cell Growth and Differentiation, vol. 9, no. 4, pp. 305–312, 1998.
- J. L. Arbiser, N. Klauber, R. Rohan et al., “Curcumin is an in vivo inhibitor of angiogenesis,” Molecular Medicine, vol. 4, no. 6, pp. 376–383, 1998.
- S. Toda, T. Miyase, H. Arichi, H Tanizawa, and Y. Takino, “Natural antioxidants. III. Antioxidative components isolated from rhizome of Curcuma longa L,” Chemical and Pharmaceutical Bulletin, vol. 33, no. 4, pp. 1725–1728, 1985.
- J. P. Gaddipati, S. V. Sundar, J. Calemine, P. Seth, G. S. Sidhu, and R. K. Maheshwari, “Differential regulation of cytokines and transcription factors in liver by curcumin following hemorrhage/resuscitation,” Shock, vol. 19, no. 2, pp. 150–156, 2003.
- S. D. Deodhar, R. Sethi, and R. C. Srimal, “Preliminary study on antirheumatic activity of curcumin (diferuloyl methane),” The Indian Journal of Medical Research, vol. 71, pp. 632–634, 1980.
- B. Lal, A. K. Kapoor, P. K. Agrawal, O. P. Asthana, and R. C. Srimal, “Role of curcumin in idiopathic inflammatory orbital pseudotumours,” Phytotherapy Research, vol. 14, no. 6, pp. 443–447, 2000.
- B. Lal, A. K. Kapoor, O. P. Asthana et al., “Efficacy of curcumin in the management of chronic anterior uveitis,” Phytotherapy Research, vol. 13, no. 4, pp. 318–322, 1999.
- R. R. Satoskar, S. J. Shah, and S. G. Shenoy, “Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation,” International Journal of Clinical Pharmacology, Therapy, and Toxicology, vol. 24, no. 12, pp. 651–654, 1986.
- R. C. Srimal and B. N. Dhawan, “Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent,” The Journal of Pharmacy and Pharmacology, vol. 25, no. 6, pp. 447–452, 1973.
- A. M. Siddiqui, X. Cui, R. Wu et al., “The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-,” Critical Care Medicine, vol. 34, no. 7, pp. 1874–1882, 2006.
- B. M. Forman, J. Chen, and R. M. Evans, “The peroxisome proliferator-activated receptors: ligands and activators,” Annals of the New York Academy of Sciences, vol. 804, no. 1, pp. 266–275, 1996.
- B. Zingarelli, M. Sheehan, P. W. Hake, M. O'Connor, A. Denenberg, and J. A. Cook, “Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsisby modulation of signal transduction pathways,” Journal of Immunology, vol. 171, no. 12, pp. 6827–6837, 2003.
- M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.
- C. Jiang, A. T. Ting, and B. Seed, “PPAR- agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.
- F. Chen, M. Wang, J. P. O'Connor, M. He, T. Tripathi, and L. E. Harrison, “Phosphorylation of PPAR via active ERK1/2 leads to its physical association with p65 and inhibition of NF-,” Journal of Cellular Biochemistry, vol. 90, no. 4, pp. 732–744, 2003.
- A. B. Kunnumakkara, S. Guha, S. Krishnan, P. Diagaradjane, J. Gelovani, and B. B. Aggarwal, “Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor--regulated gene products,” Cancer Research, vol. 67, no. 8, pp. 3853–3861, 2007.
- G. C. Jagetia and B. B. Aggarwal, ““Spicing up” of the immune system by curcumin,” Journal of Clinical Immunology, vol. 27, no. 1, pp. 19–35, 2007.
- M. Hu, Q. Du, I. Vancurova et al., “Proapoptotic effect of curcumin on human neutrophils: activation of the p38 mitogen-activated protein kinase pathway,” Critical Care Medicine, vol. 33, no. 11, pp. 2571–2578, 2005.
- D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky, “Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care,” Critical Care Medicine, vol. 29, no. 7, pp. 1303–1310, 2001.
- A. Ayala, C.-S. Chung, J. L. Lomas et al., “Shock-induced neutrophil mediated priming for acute lung injury in mice: divergent effects of TLR-4 and TLR-4/FasL deficiency,” American Journal of Pathology, vol. 161, no. 6, pp. 2283–2294, 2002.
- R. Taneja, J. Parodo, S. H. Jia, A. Kapus, O. D. Rotstein, and J. C. Marshall, “Delayed neutrophil apoptosis in sepsis is associated with maintenance of mitochondrial transmembrane potential and reduced caspase-9 activity,” Critical Care Medicine, vol. 32, no. 7, pp. 1460–1469, 2004.
- M. Collin, N. S. Patel, L. Dugo, and C. Thiemermann, “Role of peroxisome proliferator-activated receptor- in the protection afforded by 15-deoxy prostaglandin J2 against the multiple organ failure caused by endotoxin,” Critical Care Medicine, vol. 32, no. 3, pp. 826–831, 2004.
- M. Abdelrahman, A. Sivarajah, and C. Thiemermann, “Beneficial effects of PPAR- ligands in ischemia-reperfusion injury, inflammation and shock,” Cardiovascular Research, vol. 65, no. 4, pp. 772–781, 2005.
- M. Abdelrahman, M. Collin, and C. Thiemermann, “The peroxisome proliferator-activated receptor- ligand 15-deoxy prostaglandin J2 reduces the organ injury in hemorrhagic shock,” Shock, vol. 22, no. 6, pp. 555–561, 2004.
Copyright © 2007 Asha Jacob et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.